Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

Signal Pharmaceuticals is a biopharmaceutical company that was founded by David Anderson (Senior VP & Head of Research), Alan Lewis (CEO), Mark Carmen, and Jackie Johnson and is based in California. It was acquired by Celgene in 2009

Nanopharm Ltd. engages in the provision of orally inhaled and nasal drug product design and development services. It offers pre-formulation, formulation, and analytical solutions. The company was founded by Robert Price and is headquartered in Newport, the United Kingdom.

OncoMed Pharmaceuticals, Inc. is a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and is listed on NASDAQ under the stock symbol OMED.

Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Oxygen, Inc. wholesales and markets oxygen. The company was founded on June 24, 2002 and is headquartered in Elizabeth, CO.

Angiogene Pharmaceuticals Ltd., a drug discovery company, engages in developing drug candidates for the treatment of cancer and other angiogenic diseases. It develops compounds to the preclinical stage and at that point licenses to pharmaceutical and drug development companies. The company also carries out research activities on contract basis. Its product pipeline includes ZD6126, a vascular disrupting agent that acts via tubulin depolymerization; MN029, a tubulin-binding vascular disrupting agent; ANG500, a series of compounds with activity against tumour models; and ANG700, a series of hypoxia activated prodrugs. Angiogene Pharmaceuticals Ltd.

Generic Assays specialises in the manufacture of manual detection test kits and automated systems.

Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products. AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).

Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd., established on 2002-09-30, Business scope includes general items:biomedicine,herbal medicine,chemical medicine,traditional Chinese medicine,Health products,food,The introduction of agricultural products and medical equipment items and technologies,Research,Development and Pilot Test;and related technologies,Licensing of Patents and Intellectual Property,Achievement Transformation and Transfer,drug screening technology,Drug Development Technology,crop production technology,Licensing and transfer of planting technology;Technical Advisory Services,Consulting on technology and product licensing and transfer,Pharmaceutical commissioned production(For details, see Drug Registration Approval Document for Drug Marketing Authorization Holders),Drug import and export(Except for the import and export of narcotic drugs and psychotropic substances).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.

Shanghai Junshi Biosciences Co., Ltd. engages in the discovery, development, clinical research, and commercialization of biopharmaceutical drugs. Its products include toripalimab injection, UBP1211, JS002, and UBP1213. The company was founded by Zhuo Bing Zhang and Ji Kuan Shan on December 27, 2012 and is headquartered in Shanghai, China.

Peking Union Medical College Hospital, also known as Beijing Xiehe Hospital (Chinese: 北京协和医院), is a renowned general hospital in Beijing, China. It was founded in 1921 by Rockefeller Foundation and is affiliated to both Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS). During the Cultural Revolution, it was renamed the "Anti-imperialist Hospital".